Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can tracking a precancerous condition slash myeloma diagnosis delays?

NCT ID NCT05539079

Knowledge-focused Sponsor: Oxford University Hospitals NHS Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This study follows 2,000 people with monoclonal gammopathy of undetermined significance (MGUS), a condition that can precede multiple myeloma, a rare blood cancer. The goal is to measure how often MGUS progresses to myeloma and to understand current monitoring practices. Participants will complete annual questionnaires for up to five years, and some will provide blood samples. The findings could lead to better screening and earlier diagnosis of myeloma.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could improve early detection of myeloma by clarifying how MGUS progresses and how it should be monitored, potentially reducing diagnostic delays.
What could go wrong
This is an observational study, so it won't test a treatment. Results depend on long-term follow-up and may not change clinical practice immediately.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2023

Expected to finish

Dec 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants will be those with a diagnosis of Monoclonal gammopathy. Patients who are suitable for the study will be identified by the treating haemato-oncology clinician, the clinical nurse specialist, the myeloma service coordinators and at the local multidisciplinary team (MDT) meetings in the participating hospitals.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: • Any individual with a confirmed or suspected case of MGUS Exclusion Criteria: * Those who are unable or unwilling to give informed consent * Patients under the age of 18 * Patients with no evidence of MGUS * Patients with a light chain ratio of 0.3 to 3.0 without a monoclonal protein on serum electrophoresis or immunofixation * Patients with rapidly rising paraprotein or serum free light chains of progressive disease at time of diagnosis or inclusion into study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MGUS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

monoclonal gammopathy of uncertain significance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MGUS

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Secure Study

    RECRUITING

    Oxford, Oxfordshire, OX3 7LE, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.